Repligen has agreed to acquire the business of Novozymes Biopharma Sweden in a cash transaction worth up to €21 M (US$29.5 M). The acquisition will position Repligen as a key player in the supply of products used in the manufacture of biologics and will allow Novozymes to focus on the remainder of its Biopharma business unit, including hyaluronic acid, recombinant albumin products and drug delivery and protein expression technologies.